Sun Pharma报告说,尽管收入增加和EBITDA增长,但Q4FY25利润却下降了19%,降至2,154克朗。 Sun Pharma reports Q4FY25 profit down 19% to ₹2,154 crore, despite revenue rise and EBITDA growth.

Sun制药业报告,Q4FY25综合利润下降19%,达到2 154克朗,尽管收入增长8%,达到12 959克朗。 Sun Pharmaceutical Industries reported a 19% drop in Q4FY25 consolidated profit to ₹2,154 crore, despite an 8% rise in revenue to ₹12,959 crore. 该公司的EBITDA公司增加了22%,其印度配方销售增长了13.6%。 The company's EBITDA increased by 22%, and its India formulation sales grew by 13.6%. Sun Pharma宣布每股5.50英镑的红利,并注意到一笔对其财务产生影响的结算费。 Sun Pharma declared a dividend of ₹5.50 per share and noted a settlement charge impacting its financials.